Tag Archives: Quest Diagnostics

December 2023—Quest Diagnostics and Scipher Medicine announced a collaboration designed to expand patient access to diagnostic services for rheumatoid arthritis. Under a multiyear collaboration, Quest will provide RNA extraction and next-generation sequencing services for Scipher’s PrismRA test, a blood-based molecular signature response classifier aimed at predicting a patient’s response to TNF inhibitor therapy. Quest will enable specimen collection at about 7,300 patient access points and more than 2,100 patient service center locations, as well as courier services that transport patient specimens between Quest and Scipher laboratories and provider sites.

May 2023—Quest Diagnostics and Haystack Oncology, an early-stage oncology company focused on minimal residual disease testing, announced on April 27 a definitive agreement for Quest to acquire Haystack in an all-cash equity transaction.

April 2023—Quest Diagnostics unveiled Quest Advanced Specialized Transplant Services, designed to expand access to laboratory tests for transplanting solid organ, human cells, and tissue. Quest says its new offering features a menu of more than 170 specialized transplant and infectious disease tests, longitudinal trends analysis of test results in the electronic medical record, and support services that include medical consultation. Patients can access Quest’s network of 2,100 patient service centers and 5,000 mobile and at-home phlebotomists to support patient-compliant pre- and post-transplant testing. The services are available to recipients and living donors across the United States, excluding Alaska and Hawaii.  

July 2021—As the role of informatics in the practice of medicine continues to grow, so does the need to move formalized informatics education from the category of luxury to necessity, says Bruce Levy, MD, associate chief medical informatics officer at Geisinger Health System, Danville, Pa., and professor and program director of the clinical informatics fellowship at Geisinger Commonwealth School of Medicine.

June 23, 2021—Biocept announced a collaboration with Quest Diagnostics to provide laboratory testing services to Quest patients for its Target Selector NGS-based liquid biopsy targeted lung cancer panel.

January 2021—The FDA authorized the first diagnostic test for at-home collection of patient samples to detect COVID-19 and influenza A and B. Quest Diagnostics’ RC COVID-19 +Flu RT-PCR Test for prescription use was authorized with Quest’s Self-Collection Kit for COVID-19 +Flu for individuals who are suspected of respiratory viral infection consistent with COVID-19 when home collection is determined to be appropriate by an individual’s health care provider.

Dec. 7, 2020—The FDA authorized the first diagnostic test for at-home collection of patient samples to detect COVID-19 and influenza A and B.

August 2020—The FDA reissued on July 18 an emergency use authorization to Quest Diagnostics to authorize its Quest SARS-CoV-2 rRT-PCR test for use with pooled samples containing up to four individual swab specimens collected under observation. It is the first COVID-19 diagnostic test to be authorized for use with pooled samples.

July 20, 2020—The FDA reissued on July 18 an emergency use authorization to Quest Diagnostics to authorize its Quest SARS-CoV-2 rRT-PCR test for use with pooled samples containing up to four individual swab specimens collected under observation.

Feb. 25, 2020—Siemens Healthineers announced that it was selected by Quest Diagnostics to be its preferred supplier for immunoassay testing.

February 2020—Quest Diagnostics has acquired certain assets of the clinical laboratory services business of Boston Clinical Laboratories, based in Waltham, Mass.

September 2019—Quest Diagnostics announced the availability of its test panel to guide therapy with HIV pre-exposure prophylaxis, or PrEP. PrEP is the use of antiretroviral drugs to help prevent HIV infection in high-risk individuals who are not infected.

February 2019—Quest Diagnostics has signed a definitive agreement to acquire the assets of the clinical laboratory services business of Boyce and Bynum Pathology Laboratories; BBPL’s anatomic pathology division, long-term care division, and Boyce and Bynum Pathology Professional Services are not part of the transaction.

January 2019—Quest Diagnostics and Oxford Immunotec announced that Quest has completed its acquisition of the U.S. laboratory services business of Oxford Immunotec; the T-Spot.TB tuberculosis and the Accutix tick-borne disease testing services are now part of Quest’s portfolio of infectious disease testing services.

Dec. 13, 2018—Quest Diagnostics has signed a definitive agreement to acquire the assets of the clinical laboratory services business of Boyce and Bynum Pathology Laboratories; BBPL’s anatomic pathology division, long-term care division, and Boyce and Bynum Pathology Professional Services are not part of the transaction. Through a separate professional services agreement, BBPPS will become the exclusive pathology provider for Quest ...

Oct. 17, 2018—Quest Diagnostics announced it has acquired PhenoPath, a national provider of specialized anatomic pathology and related services.

July 2017—Quest Diagnostics has signed definitive agreements to acquire Med Fusion and Clear Point, both based in Lewisville, Tex., with the aim to establish a center of excellence providing diagnostic services to aid the detection and management of cancer for oncologists and patients nationwide. Baylor Scott & White Health; the US Oncology Network (the Network), supported by McKesson Specialty Health; Texas Oncology; and Pathologists Bio-Medical Laboratories are co-owners of one or both businesses.

June 2017—Quest Diagnostics and PeaceHealth have formed a two-part arrangement to enhance the delivery of laboratory services to communities in Oregon, Washington, and Alaska.

May 2017—Veracyte will extend access to its Afirma Gene Expression Classifier through an agreement with Quest Diagnostics. The agreement is intended to meet growing physician demand for innovative genomic testing services to improve thyroid cancer diagnosis.

April 2017—Quest Diagnostics launched a test service that aims to help physicians evaluate a patient’s response to drug therapies used to treat infection with the hepatitis B virus. The HBsAg qualitative test is used to aid in diagnosis of patients with HBV.

March 2016—Quest Diagnostics will offer clinical laboratory testing using Dako’s PD-L1 IHC 28-8 pharmDx qualitative test, an FDA-approved complementary in vitro diagnostic test for use in the detection of PD-L1 expression in formalin-fixed, paraffin-embedded melanoma tissue.

June 2015—LeukoVantage, an evidence-based genomic test service that aids in the diagnosis, prognosis, monitoring, and selection of treatment for myeloid neoplasms is now available from Quest Diagnostics. The lab-developed test uses next-generation sequencing, polymerase chain reaction, and other techniques to interrogate DNA from leukocytes in blood or bone marrow specimens for the presence of mutations in 30 genes most frequently associated with myeloid neoplasms.

March 2014—Quest Diagnostics will collaborate with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis, and treatment for four strains of viral hepatitis in the U.S. Under terms of the multiyear contract, Quest will provide CDC researchers with analytics expertise and access to the company’s national Health Trends database of de-identified clinical testing hepatitis data.

January 2015—Quest Diagnostics now offers BRC­Avantage Plus, the company’s first suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non-BRCA and BRCA genes.

June 2014—Quest Diagnostics launched MyQuest by Care360 at QuestDiagnostics.com/MyQuest, a secure patient portal that enables patients to view copies of their lab test reports from Quest.

May 2014—Quest Diagnostics is offering new pathology and blood tests for identifying and assessing an individual’s risk of Lynch syndrome.

April 2014—UC San Francisco and Quest Diagnostics formed a collaboration to accelerate the translation of biomedical research into advanced diagnostics in the field of precision medicine for improved patient care, treatment, and outcomes.

December 2013—Quest Diagnostics now offers BRCAvantage, a suite of four lab-developed genetic tests that identify mutations in BRCA1 and BRCA2 genes. The BRCAvantage test is performed using next-generation sequencing and multiplex ligation-dependent probe amplification to detect all published deleterious mutations in BRCA1 and BRCA2.

Quest Diagnostics and Hologic have entered into a strategic alliance to more broadly offer testing based on Hologic’s Aptima family of products, as well as to co-develop and promote advanced diagnostic solutions to improve women’s health.

Quest Diagnostics has entered into a definitive agreement to acquire laboratory-related clinical outreach service operations of Dignity Health, a hospital system based in California. Under the agreement, Quest will acquire operations through which Dignity Health provides outreach diagnostic information services to patients and physician offices in parts of California and Nevada.

Quest Diagnostics offers a clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.